Chronic Kidney Disease in Children (CKiD IV)

项目摘要 儿童慢性肾脏病研究（CKiD）是一项多中心、前瞻性、观察性队列研究。 研究入组时轻度至中度肾功能受损的6个月至16岁儿童。两 费城儿童医院（CHOP）的临床协调中心（CCC）和儿童慈善机构 医院（CMH）和约翰霍普金斯彭博公共卫生学院的数据协调中心 达成合作协议进行这项研究。自2003年成立以来，CKiD的科学目标 已经确定了肾功能下降的危险因素和肾功能下降的影响， 心血管疾病的危险因素、生长障碍及其相关发病率、神经认知功能 和行为。本申请的目的是申请资金，以便从2018年8月开始继续进行队列研究 到2023年7月目前提案的目标将扩大到包括完成 招募了190名患有先天性肾脏和泌尿道异常以及其他非肾小球疾病的儿童， CKD病程早期的肾脏疾病，CKD持续时间、透析和 肾移植对心血管危险因素累积负荷的远程评估 活动和血压，开发新的方法来识别CKD进展的风险因素， 通过与其他队列合作加强儿童CKD研究，并继续提供 为科学界提供广泛的数据资源。中西部临床的主要研究者 CMH的协调中心在儿童肾脏疾病、临床研究设计、 招募和保留，研究程序的质量控制，以及组织跨 CKiD的多个参与研究中心。CKiD研究评估了一个地理和种族多样化的队列。 CKiD的结构及其对辅助研究的支持继续刺激新知识的产生 与CKD进展以及相关合并症的发展和演变有关，以及 这些数据的公布。CKiD的基础设施继续作为职业发展的平台 初级研究人员的发展奖，以及高级同事的辅助R01。最重要的是， 随着CKD病程早期随访时间的延长和受试者招募的增加，我们将继续 描述与CKD进展及其后遗症相关的新的肾损伤生物标志物， 为未来的治疗试验提供信息。

PROJECT SUMMARY The Chronic Kidney Disease in Children Study (CKiD) is a multi-center, prospective, observational cohort study of children aged 6 months to 16 years with mild to moderately impaired kidney function at study entry. Two clinical coordinating centers (CCCs) at the Children's Hospital of Philadelphia (CHOP), and Children's Mercy Hospital (CMH), and a data coordinating center at Johns Hopkins Bloomberg School of Public Health have formed a cooperative agreement to conduct this study. Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and the effects of kidney function decline on the risk factors for cardiovascular disease, growth failure and its associated morbidity, neurocognitive function and behavior. The purpose of this application is to request funds to continue the cohort study from August, 2018 to July, 2023. The aims of the current proposal will expand on the original aims to include completion of recruitment of 190 children with congenital anomalies of the kidney and urinary tract and other non-glomerular kidney disorders early in the course of CKD, characterization of the impact of duration of CKD, dialysis and kidney transplantation on the cumulative burden of cardiovascular risk factors, remote assessment of physical activity and blood pressure, development of novel approaches to identify risk factors for CKD progression, enhancement of research in childhood CKD through collaboration with other cohorts, and continued provision of a broad data resource for the scientific community. The Principal Investigator of the Midwest Clinical Coordinating Center at CMH has clinical expertise in kidney disease in children, clinical research design, recruitment and retention, quality control of study procedures, and organization of collaboration across the multiple participating sites in CKiD. The CKiD study encompassess a geographically and racially diverse cohort. The structure of CKiD and its support of ancillary studies continues to stimulate the generation of new knowledge pertaining to the progression of CKD and the development and evolution of associated co-morbidities, as well as the publication of those data. The infrastructure of CKiD continues to serve as a platform for career development awards for junior investigators, and ancillary R01s for more senior colleagues. Most importantly, with longer follow-up and additional recruitment of subjects early in the course of CKD, we will contiune to characterize novel biomarkers of kidney inury that are associated with CKD progression and its sequellae to help inform future therapeutic trials.